May 6th, 2013
Latest Biotech News Stock Review Calls and Forecasts:
The turning point for Bio-Matrix Scientific (BMSN) was the authorizing of 1,000,000 shares of the Series AAA Preferred Stock, now BMSN is getting ready to run back to new highs forecasts Johnny. Whispers are that Roche and BMSN are meeting in Switzerland this coming week predicts Biotech News Stock Review, if that happens and leaks out then shareholders of BMSN could find themselves laughing all the way to the bank ventures Johnny!
Pfizer (PFE) to score the deal of the century when it buys out struggling Delcath Systems (DCTH) predicts Biotech News Stock Review. DCTH share price has been taking a beating and the company is now low hanging fruit for PFE ventures Adam. Adam also believes PFE has an offer on the table and that initially DCTH was reluctant to accept it but things have changed now and PFE may even withdraw any offer as it attempts to minimize any acquisition costs projects Johnny.
The Drug Enforcement Agency (DEA) has reached it’s scheduling decision on Arena Pharmaceutical’s (ARNA) obesity drug Belviq predicts Biotech News Stock Review. Look for the decision to come out this week forecasts Adam.
May 2nd, 2013 Latest Biotech News Stock Review Calls and Forecasts:
Following the negative FDA Advisory Committee vote Delcath Systems (DCTH) rushing to accept potential Pfizer (PFE) buyout offer projects Biotech News Stock Review. Johnny believes that an offer is on the table and with DCTH stock set to plummet an offer that might not have been so great now looks very appealing!
Biotech News Stock Review called it! Following announcement of Bio-Matrix Scientific (BMSN) authorizing 1,000,000 shares of the Series AAA Preferred Stock the share price surges 55%. Adam says that a buyout is coming sooner than you think, Biotech News Stock Review is now projecting a bidding war between Roche and Pfizer.
April 28th, 2013 Latest Biotech News Stock Review Calls and Forecasts:
Delcath Systems (DCTH) and Pfizer (PFE) big announcement coming projects Biotech News Stock Review. Adam believes that the dotting of the i’s and crossing of the t’s is all that’s remaining and to watch for an official PR within the next 14 days!
Biotech News Stock Review predicts shareholders of Bio-Matrix Scientific (BMSN) can expect a great week ahead. It’s been pretty rough lately for longs as the stock ended at .0024 on Friday. Johnny is very excited about what he has found out and believes that BMSN is going to release a very substantial PR that will quickly get this stock heading back to pennyland!
Adam confirms to Biotech News Stock Review that Arena Pharmaceuticals (ARNA) will receive European Medical Association (EMA) approval, watch for the official announcement coming! Adam projects that this will be the catalyst that takes ARNA to new heights and rewards all the long shareholders!
Amarantus BioScience (AMBS) is talking with a big pharmaceutical, Biotech News Stock Review projects that it is Pfizer (PFE) who have been very active in the merger and acquisition field as they try to shore up their revenues, with major patents expiring PFE is going after small biotechs like AMBS. Watch for official news that will send AMBS share price soaring!
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was instrumental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing. Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts. If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
FDA Approval Calender 2013
Clinical trial news by Drugs.com